LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Coherus Oncology Inc

Aperta

SettoreSettore sanitario

1.34 -1.47

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.33

Massimo

1.39

Metriche Chiave

By Trading Economics

Entrata

354M

298M

Vendite

2.7M

10M

P/E

Media del settore

2.189

35.733

Margine di Profitto

2,903.911

Dipendenti

177

EBITDA

-1.3M

-45M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+212.4% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

34M

135M

Apertura precedente

2.81

Chiusura precedente

1.34

Notizie sul Sentiment di mercato

By Acuity

75%

25%

346 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2025, 23:59 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 set 2025, 22:02 UTC

I principali Market Mover

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 set 2025, 17:01 UTC

I principali Market Mover

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 set 2025, 17:01 UTC

I principali Market Mover

Tron Shares Rise After New Investment From Bravemorning

8 set 2025, 16:14 UTC

I principali Market Mover

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 set 2025, 16:13 UTC

I principali Market Mover

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 set 2025, 22:56 UTC

Discorsi di Mercato

Worst May Be Over for New Zealand Retailers -- Market Talk

8 set 2025, 22:23 UTC

Discorsi di Mercato

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 set 2025, 21:51 UTC

Discorsi di Mercato

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 set 2025, 21:47 UTC

I principali Market Mover

Microsoft Signs $17.4B AI Deal With Nebius

8 set 2025, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 set 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 set 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 set 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 19:33 UTC

Discorsi di Mercato

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 set 2025, 19:22 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 set 2025, 19:02 UTC

Discorsi di Mercato

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 set 2025, 17:29 UTC

Discorsi di Mercato

Mexican Inflation Seen Little Changed in August -- Market Talk

8 set 2025, 16:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 set 2025, 16:36 UTC

Discorsi di Mercato

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 set 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 16:16 UTC

Utili

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 set 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 set 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

212.4% in crescita

Previsioni per 12 mesi

Media 4.03 USD  212.4%

Alto 7 USD

Basso 1.1 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

346 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat